Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28998972 | 0.89 | NTRK1 (0.34) | NTRK1POLBMAPTMEN1KMT2A | |
| SCHEMBL30228388 | 0.89 | NTRK1 (0.34) | NTRK1POLBMAPTMEN1KMT2A | |
| SCHEMBL25108645 | 0.89 | NTRK1 (0.34) | NTRK1POLBMAPTMEN1KMT2A | |
| SCHEMBL25109370 | 0.87 | NTRK1 (0.34) | NTRK1POLBMAPTMEN1KMT2A | |
| SCHEMBL29541739 | 0.84 | NPC1 (0.35) | NPC1RAB9APOLBMAPTMEN1 | |
| SCHEMBL25624058 | 0.84 | NPC1 (0.35) | NPC1RAB9APOLBMAPTMEN1 | |
| SCHEMBL25624074 | 0.82 | NPC1 (0.37) | NPC1RAB9APOLBMAPTMEN1 | |
| SCHEMBL25108642 | 0.81 | ALK (0.37) | NTRK1POLB | |
| SCHEMBL25107923 | 0.78 | TRPV1 (0.36) | — | |
| SCHEMBL25624939 | 0.78 | ALK (0.32) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, PAICS | NTRK1 3845/4885NPC1 273/4885RAB9A 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.